EVMN vs IMVT
EVMN: Evommune is a clinical-stage biotechnology company developing novel treatments for inflammatory diseases, currently advancing a pipeline of product candidates including EVO756 and EVO301. IMVT: Immunovant is a clinical-stage immunology company developing IMVT-1402, a potentially best-in-class FcRn inhibitor to treat autoimmune diseases driven by pathogenic IgG antibodies.
Side-by-side fundamentals
| Metric | EVMN | IMVT | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $11.40 | $39.05 | |
| Market cap as of 2026-07-23 | $439M | $8.0B | |
| PEG as of 2026-07-23 | n/a | -11.69 | |
| Net margin as of 2026-07-23 | -606.2% | n/a | |
| Operating margin as of 2026-07-23 | -744.4% | n/a | |
| ROE as of 2026-07-23 | -33.5% | -68.2% | EVMN higher |
| ROA as of 2026-07-23 | -30.6% | -62.2% | EVMN higher |
| Debt / equity as of 2026-07-23 | 0.00 | 0.00 | IMVT lower |
| Revenue growth (YoY) as of 2026-07-23 | +85.7% | n/a | |
| Beta as of 2026-07-23 | -0.30 | 0.81 | |
| 1-year return as of 2026-07-22 close | -28.6% | +123.3% | IMVT higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.